Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

被引：0
|
作者：
Brian R. Ott
Lesley M. Blake
Ethel Kagan
Malca Resnick
机构：
[1] Rhode Island Hospital – APC 6,The Alzheimer’s Disease & Memory Disorders Center
[2] Northwestern University,Department of Psychiatry
[3] Harborside Financial Center,Forest Laboratories, Inc.
来源：
Journal of Neurology | 2007年 / 254卷
关键词：
Alzheimer’s disease; memantine; open label; randomized controlled trial; ADAS-cog;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：351 / 358
页数：7
相关论文
共 50 条
  • [21] An Open-Label, Multicenter Observational Study for Patients with Alzheimer's Disease Treated with Memantine in the Clinical Practice
    Stamouli, S. S.
    Tzanakaki, M.
    Giatas, S.
    Georgiadis, G.
    Papalexi, E.
    Parashos, I. A.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2011, 1 (01): : 10 - 19
  • [22] Combination treatment with galantamine and memantine: Safety data in patients with mild to moderate Alzheimer's disease
    Crivera, C.
    Amatniek, J.
    Zhu, Y.
    Rupnow, M.
    Parsons, L.
    Cimms, T.
    Verhoff, R.
    Donnelly, S.
    Van Oene, J. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 59 - 59
  • [23] Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study
    Salloway, Stephen
    Marshall, Gad A.
    Lu, Ming
    Brashear, H. Robert
    CURRENT ALZHEIMER RESEARCH, 2018, 15 (13) : 1231 - 1243
  • [24] Long-term treatment with the NMDA antagonist, memantine:: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease
    Ferris, SH
    Schmitt, FA
    Doody, R
    Möbius, HJ
    Stöffler, A
    Reisberg, B
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 258 - 259
  • [25] Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
    Doody, RS
    Geldmacher, DS
    Gordon, B
    Perdomo, CA
    Pratt, RD
    ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 427 - 433
  • [26] An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease
    Gordon, Marc
    Kingsley, Peter
    Goldberg, Terry
    Koppel, Jeremy
    Christen, Erica
    Keehlisen, Lynda
    Kohn, Nina
    Davies, Peter
    NEUROLOGY, 2012, 78
  • [27] An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease
    Gordon, Marc L.
    Kingsley, Peter B.
    Goldberg, Terry E.
    Koppel, Jeremy
    Christen, Erica
    Keehlisen, Lynda
    Kohn, Nina
    Davies, Peter
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2012, 2 (01): : 312 - 320
  • [28] Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
    Ueda, Kengo
    Katayama, Sadao
    Arai, Tetsuaki
    Furuta, Nobuo
    Ikebe, Shinichiro
    Ishida, Yoshinori
    Kanaya, Kiyoshi
    Ouma, Shinji
    Sakurai, Hirofumi
    Sugitani, Masato
    Takahashi, Makio
    Tanaka, Toshihisa
    Tsuno, Norifumi
    Wakutani, Yosuke
    Shekhawat, Ankita
    Das Gupta, Ayan
    Kiyose, Kazuki
    Toriyama, Kazuhiro
    Nakamura, Yu
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2019, 9 (02) : 302 - 318
  • [29] Adding memantine to therapy with rivastigmine in patients with mild to moderate Alzheimer's disease: Results of a 12-week pilot study
    Riepe, MW
    Adler, G
    Ibach, B
    Tracik, F
    NEUROLOGY, 2005, 64 (06) : A363 - A364
  • [30] Long-term efficacy and safety benefits from treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease
    Moebius, HJ
    Reisberg, B
    Schmitt, F
    Doody, R
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S388 - S389
12345